Plasma deoxysphingolipids: A novel class of biomarkers for the metabolic syndrome?

Diabetologia

Volumn 55, Issue 2, 2012, Pages 421-431

  Othman, A ^a,b,d   Rutti M F ^a,c   Ernst, D ^a,b   Saely, C H ^e,f,g   Rein, P ^e,f,g   Drexel, H ^e,f,g,h   Porretta Serapiglia, C ⁱ   Lauria, G ⁱ   Bianchi, R ⁱ   Von Eckardstein, A ^a,b,d   Hornemann, T ^a,b,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Hospital Wil   (Switzerland)

^d Competence Centre for Systems Physiology and Metabolic Diseases ^*  (Switzerland)

^e Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^f Academic Teaching Hospital Feldkirch   (Austria)

^g PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^h DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Atypical sphingolipids; Biomarker; Deoxysphingolipids; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

BIOLOGICAL MARKER; DEOXYSPHINGOLIPID; SPHINGOLIPID; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; RISK FACTOR; STREPTOZOCIN DIABETES;

AGED; ANIMALS; BIOLOGICAL MARKERS; CATALYSIS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; RATS; RISK; SERINE C-PALMITOYLTRANSFERASE; SPHINGOLIPIDS; STREPTOZOCIN;

EID: 84856696054     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2384-1     Document Type: Article

References (32)

1. IUPAC-IUB Commission on Biochemical Nomenclature 1978 The nomenclature of lipids (Recommendations 1976) IUPAC-IUB Commission on Biochemical Nomenclature Biochem J 171 21 35
2. MY Donath PA Halban 2004 Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications Diabetologia 47 581 589 14767595 10.1007/s00125-004-1336-4 1:STN:280:DC%2BD2c7mtVChug%3D%3D (Pubitemid 38491259)
3. SE Kahn RL Hull KM Utzschneider 2006 Mechanisms linking obesity to insulin resistance and type 2 diabetes Nature 444 840 846 17167471 10.1038/nature05482 1:CAS:528:DC%2BD28XhtlShtrzP (Pubitemid 46024990)
4. M Prentki CJ Nolan 2006 Islet beta cell failure in type 2 diabetes J Clin Invest 116 1802 1812 16823478 10.1172/JCI29103 1:CAS:528:DC%2BD28XmvV2ltLs%3D (Pubitemid 44033300)
5. RA DeFronzo 2010 Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 Diabetologia 53 1270 1287 20361178 10.1007/s00125-010-1684-1 1:CAS:528:DC%2BC3cXmsFyrs7w%3D
6. JD McGarry 1992 What if Minkowski had been ageusic? An alternative angle on diabetes Science 258 766 770 1439783 10.1126/science.1439783 1:STN:280:DyaK3s%2FmvValsg%3D%3D
7. JA Chavez SA Summers 2010 Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms Biochim Biophys Acta 1801 252 265 19796706 1:CAS:528:DC%2BC3cXitVejtLo%3D
8. JM Olefsky CK Glass 2010 Macrophages, inflammation, and insulin resistance Annu Rev Physiol 72 219 246 20148674 10.1146/annurev-physiol-021909- 135846 1:CAS:528:DC%2BC3cXktFKkt70%3D
9. LA Cowart 2009 Sphingolipids: players in the pathology of metabolic disease Trends Endocrinol Metab 20 34 42 19008117 10.1016/j.tem.2008.09.004 1:CAS:528:DC%2BD1MXkt1ahsw%3D%3D
10. SA Summers 2006 Ceramides in insulin resistance and lipotoxicity Prog Lipid Res 45 42 72 16445986 10.1016/j.plipres.2005.11.002 1:CAS:528: DC%2BD28XhtV2ksbg%3D (Pubitemid 43170804)
11. GM Deevska MN Nikolova-Karakashian 2011 The twists and turns of sphingolipid pathway in glucose regulation Biochimie 93 32 38 20561942 10.1016/j.biochi.2010.05.016 1:CAS:528:DC%2BC3cXhsFyrs7fF
12. WL Holland JT Brozinick LP Wang, et al. 2007 Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance Cell Metab 5 167 179 17339025 10.1016/j.cmet.2007.01.002 1:CAS:528:DC%2BD2sXjsF2qtL8%3D
13. T Hornemann A Penno MF Rutti, et al. 2009 The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases J Biol Chem 284 26322 26330 19648650 10.1074/jbc.M109.023192 1:CAS:528:DC%2BD1MXhtFCgs7%2FE
14. NC Zitomer T Mitchell KA Voss, et al. 2009 Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxy-sphinganine: a novel category of bioactive 1-deoxy-sphingoid bases and 1-deoxy-dihydroceramides biosynthesized by mammalian cell lines and animals J Biol Chem 284 4786 4795 19095642 10.1074/jbc.M808798200 1:CAS:528:DC%2BD1MXhvVSgtbY%3D
15. A Penno MM Reilly H Houlden, et al. 2010 Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids J Biol Chem 285 11178 11187 20097765 10.1074/jbc.M109.092973 1:CAS:528:DC%2BC3cXktFGlsL8%3D
16. HU Humpf EM Schmelz FI Meredith, et al. 1998 Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor J Biol Chem 273 19060 19064 9668088 10.1074/jbc.273.30.19060 1:CAS:528:DyaK1cXltFGrtLw%3D (Pubitemid 28366299)
17. W Hu J Bielawski F Samad AH Merrill Jr LA Cowart 2009 Palmitate increases sphingosine-1-phosphate in C2C12 myotubes via upregulation of sphingosine kinase message and activity J Lipid Res 50 1852 1862 19369694 10.1194/jlr.M800635-JLR200 1:CAS:528:DC%2BD1MXhtVCgsrfO
18. P Felig J Wahren R Hendler T Brundin 1974 Splanchnic glucose and amino acid metabolism in obesity J Clin Invest 53 582 590 11344573 10.1172/JCI107593 1:CAS:528:DyaE2cXotFaguw%3D%3D
19. J Wahren P Felig E Cerasi R Luft 1972 Splanchnic and peripheral glucose and amino acid metabolism in diabetes mellitus J Clin Invest 51 1870 1878 5032528 10.1172/JCI106989 1:STN:280:DyaE383gsVWnsQ%3D%3D
20. CH Saely A Vonbank P Rein, et al. 2008 Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis Clin Chim Acta 397 82 86 18708042 10.1016/j.cca.2008.07.024 1:CAS:528:DC%2BD1cXhtFamsr3L
21. RT Riley WP Norred E Wang AH Merrill 1999 Alteration in sphingolipid metabolism: bioassays for fumonisin- and ISP-I-like activity in tissues, cells and other matrices Nat Toxins 7 407 414 11122537 10.1002/1522-7189(199911/12)7: 6<407::AID-NT84>3.0.CO;2-0 1:CAS:528:DC%2BD3MXktlWhtQ%3D%3D (Pubitemid 32014326)
22. J Trygg S Wold 2002 Orthogonal projections to latent structures (O-PLS) J Chemometr 16 119 128 10.1002/cem.695 1:CAS:528:DC%2BD38XitFClu7c%3D
23. M Bylesjö M Rantalainen O Cloarec JK Nicholson E Holmes J Trygg 2006 OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification J Chemometr 20 341 351 10.1002/cem.1006
24. H Tsutsui T Maeda T Toyo'oka, et al. 2010 Practical analytical approach for the identification of biomarker candidates in prediabetic state based upon metabonomic study by ultraperformance liquid chromatography coupled to electrospray ionization time-of-flight mass spectrometry J Proteome Res 9 3912 3922 20557141 10.1021/pr100121k 1:CAS:528:DC%2BC3cXosVWitLc%3D
25. Y Qiu G Cai M Su, et al. 2010 Urinary metabonomic study on colorectal cancer J Proteome Res 9 1627 1634 20121166 10.1021/pr901081y 1:CAS:528:DC%2BC3cXitV2hs70%3D
26. O Quehenberger AM Armando AH Brown, et al. 2010 Lipidomics reveals a remarkable diversity of lipids in human plasma J Lipid Res 51 3299 3305 20671299 10.1194/jlr.M009449 1:CAS:528:DC%2BC3cXhsVWgt7vN
27. M Bertea MF Rutti A Othman, et al. 2010 Deoxysphingoid bases as plasma markers in diabetes mellitus Lipids Health Dis 9 84 20712864 10.1186/1476-511X-9-84
28. M Kamaura K Nishijima M Takahashi T Ando S Mizushima O Tochikubo 2010 Lifestyle modification in metabolic syndrome and associated changes in plasma amino acid profiles Circ J 74 2434 2440 20834187 10.1253/circj.CJ-10-0150 1:CAS:528:DC%2BC3cXhsFKntLvE
29. T Illig C Gieger G Zhai, et al. 2010 A genome-wide perspective of genetic variation in human metabolism Nat Genet 42 137 141 20037589 10.1038/ng.507 1:CAS:528:DC%2BD1MXhs1Skur7M
30. AA Hicks PP Pramstaller A Johansson, et al. 2009 Genetic determinants of circulating sphingolipid concentrations in European populations PLoS Genet 5 e1000672 19798445 10.1371/journal.pgen.1000672
31. FS Eichler T Hornemann A McCampbell, et al. 2009 Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1 J Neurosci 29 14646 14651 19923297 10.1523/JNEUROSCI.2536-09. 2009 1:CAS:528:DC%2BD1MXhsVOhsLfI
32. TD Wiggin KA Sullivan R Pop-Busui A Amato AA Sima EL Feldman 2009 Elevated triglycerides correlate with progression of diabetic neuropathy Diabetes 58 1634 1640 19411614 10.2337/db08-1771 1:CAS:528:DC%2BD1MXos1Cqu70%3D